$EXEL: Exelixis Q4 Earnings Preview

Date: Monday, February 11th, 2019

Stock(s) mentioned:

Source: Seeking Alpha (https://seekingalpha.com)

Summary: Exelixis (NASDAQ:EXEL) is scheduled to announce Q4 earnings results on Tuesday, February 12th, after market close. The consensus EPS Estimate is $0.23 …

Full article address: https://seekingalpha.com/news/3431756-exelixis-q4-earnings-preview

Related News:

$EXEL: Exelixis and Iconic Therapeutics Enter into Exclusive Option and …

$BMY $MRK $PFE $EXEL: Pfizer’s Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer

$EXEL $TWTR: These 3 Value Stocks Are Absurdly Cheap Right now

$EXEL: Daiichi Sankyo launches MINNEBRO tablets in Japan

$EXEL: Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO

$CSCO $RUN $ZBRA $EQM $EXEL $TTD: Cisco Systems, Sunrun, Zebra Technologies: ‘Mad Money’ Lightning Round

$ETSY $ZBRA $EQM $EXEL: Cramer Remix: Charts suggest the market could soon get a deep correction

$ZBRA $ETSY $EQM $EXEL $TTD: Cramer’s lightning round: Zebra Technologies is a fast grower we champion

$EXEL $NVS: Exelixis Expands Its Sales

$EXEL: Here’s What Exelixis, Inc.’s (NASDAQ:EXEL) P/E Ratio Is Telling Us

$BMY $RHHBY $PFE $EXEL: Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1

Latest News:

$AVTR $FSLY $LK $LYFT $PINS $UBER: Why the IPO Boom Will Continue

$SBUX: Millions of Americans Could Miss Work Tomorrow After the ‘Game of Thrones’ Finale

$AMZN $OXY $APC $WFC $SRE: Want to invest like Warren Buffett? Here are the ins and outs of buying preferred stock

$TSLA $GM: Tesla fires could dampen electric car sales as industry ramps up EV production, auto analysts say

$ROKU $GH $CVNA: 3 Stocks That Have Doubled in 2019 — Are They Still Buys?

$AXSM: Here’s Why You’ll Regret Ignoring This Biotech Stock Rocket

$MMM: Market Loses Its Hopium-Induced High, Falls 4 Weeks Straight

$TLRY $ACB: How Did Tilray Stack Up to the Competition?

$BAH: Booz Allen Has Been a Big Winner, but the Best May Be Yet to Come

$ICPT $GILD: Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences

$JFIN: 3 Reasons iQiyi Held Up Better Than Baidu